single20MG
Tesamorelin
20MG Protocol
Tesamorelin 20MG
Injection Freq.
Inject once daily
Cycle Sched.
12–26 weeks; clinical trials support up to 52 weeks with monitoring
Reconstitution
3.0 mL BAC water
Reduction in visceral adipose tissue reported after 3–6 months
Improved lipid profile
potential liver-fat reduction in NAFLD research
Potential cognitive benefits in older adults (research ongoing)
Maintained benefits with continuous use up to ~52 weeks (as described)
1
Reconstitution Requirements
- 3.0 mL BAC water
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–1 | 1 mg / 1000 mcg | 15 |
| 2 | Weeks 2+ | 2 mg / 2000 mcg | 30 |
Inject once daily
12–26 weeks; clinical trials support up to 52 weeks with monitoring
The 20 mg tesamorelin protocol describes the same core biology as other vial sizes: tesamorelin mimics endogenous GHRH and activates pituitary GHRH receptors. This signaling prompts the pituitary to release growth hormone in pulses, which subsequently raises IGF-1 levels and is linked to lipolysis, protein-synthesis signaling, and broader metabolic effects. The page summarizes clinical outcomes in HIV-associated lipodystrophy showing reductions in visceral adipose tissue and improved lipid profiles across 6–12 months. It also highlights additional research directions, including reductions in liver fat in NAFLD and potential improvements in cognitive outcomes in older adults by countering age-related GH/IGF-1 decline. Safety considerations described include IGF-1 elevation (requiring monitoring in studies), plus musculoskeletal symptoms and fluid-related effects in some users. Mechanistically, it is positioned as an upstream GH-axis stimulator that preserves pulsatility rather than delivering exogenous GH.
Injection-site reactions (redness/itching/pain/bruising)
Joint pain and muscle aches
Peripheral edema
Carpal-tunnel–like symptoms (tingling/numbness)
IGF-1 elevation requiring monitoring
small HbA1c increases reported
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)